A different kind of test
Data-driven decision making –
a better experience for patient and clinician.
The first best test for cancer
The PinPoint Test is a clinical decision support tool offering intelligent triage for patients based on their individual risk of cancer.
It is designed to be the first best test for cancer when a patient presents with symptoms, increasing confidence in decision making for the patient at that critical early stage.
Are you a physician or healthcare provider and want to know more about how the PinPoint Test can help your patients?
Click below to request more info.
How does it work?
One draw of blood is taken as normal and processed in a standard pathology lab. 30 standard analytes plus age and sex – a total of 32 data points – are sent to PinPoint algorithms hosted on a local provider-owned server.
A result is instantly returned to the clinician indicating a risk score for cancer.
Results will be returned with a ‘Red, Amber, Green’ (RAG) system for recommended course of action:
Green – Low risk (rule-out)
Amber – Average risk (continue standard assessment)
Red – High risk (prioritise)
Thresholds can be customised to suit the use case, based on population, cancer prevalence or the type of challenges faced in local healthcare systems. See details below.
PinPoint helps the patient, the doctor and the whole healthcare system…
Rule Out
- Peace of mind for patients and their doctors, without the need for exhaustive testing and anxious waits.
- Managing capacity in healthcare systems to avoid overloading of diagnostic services.
- Safely reduced number of patients being investigated without increasing the risk of false negatives.
Prioritisation
- Transform the first-come first-served system to one that manages patient flow by individual risk.
- Shorten the timeline to confirmed diagnosis and start of treatment.
- Make cancer services more resilient to system shocks like COVID-19, so that even under extreme pressure cancer services maintain focus on high-risk patients.
What cancers do we test for?
PinPoint is building tests for 5 priority cancer groups
The test for each pathway has been undergoing an NHS service evaluation to see how the test performs in the real world. Over 17,000 tests have been completed, revealing some very exciting results, meaning the first versions of the test are now becoming available for deployment.
Upper GI
Oesophagus
Stomach
Duodenum
Small bowel
Pancreas
Liver
Bile ducts
Gallbladder
Lower GI
Colon
Rectal
Anal
Gynaecological
Cervical
Ovarian
Uterine/endometrial
Vaginal
Vulval
Lung
Small cell
Non-small cell
Head & Neck
Oral cavity
Pharyngeal
Laryngeal
Salivary gland
Nasal and sinus
Cervical lymph node
Complex skin cancers
Thyroid
If you are a clinician or represent a healthcare organisation and are interested in exploring how the PinPoint Test could help your patients, please contact us here